Literature DB >> 8423381

Amyopathic dermatomyositis: a review.

R L Euwer1, R D Sontheimer.   

Abstract

Jim Gilliam's research interests throughout his career were forced upon better defining the relationships that exist between the cutaneous and systemic manifestations of the rheumatic diseases. Although the majority of his time was spent studying such relationships in lupus erythematosus patients, he was also intensely interested in dermatomyositis (DM) in this regard as well. He was particularly intrigued with the dissociation of the cutaneous and muscular manifestations of this disorder that occasionally occurs. The term "dermatomyositis siné myositis" has been used in the past to describe patients who present with only the cutaneous manifestations of DM; however, very little published data is available from systematic examinations of such patients. For several reasons, we have preferred the term "amyopathic dermatomyositis" to describe that rare patient who for long periods of time suffers from the classical skin lesions of DM as the only clinically significant manifestation of their disease. In this presentation, we review our own personal experience with a group of six such patients and compare and contrast it to that of other workers who have dealt with this subject over the past two decades.

Entities:  

Mesh:

Year:  1993        PMID: 8423381     DOI: 10.1111/1523-1747.ep12356896

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  30 in total

1.  Amyopathic dermatomyositis.

Authors:  Sherezade Khambatta; Christopher M Wittich
Journal:  Mayo Clin Proc       Date:  2010-11       Impact factor: 7.616

Review 2.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 3.  Juvenile dermatomyositis.

Authors:  Michelle Batthish; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 4.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 5.  MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2017-04

6.  Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.

Authors:  Kuang-Hui Yu; Yeong-Jian Jan Wu; Chang-Fu Kuo; Lai-Chu See; Yu-Ming Shen; Hsiao-Chun Chang; Shue-Fen Luo; Huei-Huang Ho; I-Jung Chen
Journal:  Clin Rheumatol       Date:  2011-09-14       Impact factor: 2.980

Review 7.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

8.  Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis.

Authors:  Hua Cao; Tanvi N Parikh; Jie Zheng
Journal:  Clin Rheumatol       Date:  2009-03-18       Impact factor: 2.980

9.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

10.  Dermatomyositis with hemorrhagic myositis.

Authors:  Masashi Yamagishi; Shunji Tajima; Aki Suetake; Hidenori Kawakami; Takeo Watanabe; Hideyuki Kuriyama; Toshinori Takada; Eiichi Suzuki; Fumitake Gejyo
Journal:  Rheumatol Int       Date:  2008-12-17       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.